

Ronnie Fass

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4697155/publications.pdf>

Version: 2024-02-01

32
papers

1,120
citations

623734

14
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

772
citing authors

#	ARTICLE	IF	CITATIONS
1	Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. Neurogastroenterology and Motility, 2021, 33, e14058.	3.0	468
2	Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 4865-4882.	2.4	138
3	ESNM/ANMS consensus paper: Diagnosis and management of refractory gastroesophageal reflux disease. Neurogastroenterology and Motility, 2021, 33, e14075.	3.0	68
4	The 2011-2014 prevalence of eosinophilic oesophagitis in the elderly amongst 10 million patients in the United States. Alimentary Pharmacology and Therapeutics, 2015, 41, 1016-1022.	3.7	51
5	The role of pain modulators in esophageal disorders - no pain no gain. Neurogastroenterology and Motility, 2014, 26, 603-610.	3.0	48
6	Unmet Needs in the Treatment of Gastroesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 2015, 21, 309-319.	2.4	44
7	Review article: the current treatment of noncardiac chest pain. Alimentary Pharmacology and Therapeutics, 2016, 43, 213-239.	3.7	44
8	Utilisation of surgical fundoplication for patients with gastroesophageal reflux disease in the USA has declined rapidly between 2009 and 2013. Alimentary Pharmacology and Therapeutics, 2016, 43, 1124-1131.	3.7	42
9	Esophagogastric junction outflow obstruction. Neurogastroenterology and Motility, 2021, 33, e14193.	3.0	35
10	Treatment of Esophageal Motility Disorders Based on the Chicago Classification. Current Treatment Options in Gastroenterology, 2014, 12, 441-455.	0.8	21
11	The effect of sleep deficiency on esophageal acid exposure of healthy controls and patients with gastroesophageal reflux disease. Neurogastroenterology and Motility, 2019, 31, e13705.	3.0	21
12	The relationship between length of Barrett's oesophagus mucosa and body mass index. Alimentary Pharmacology and Therapeutics, 2015, 41, 137-144.	3.7	17
13	Naps Are Associated More Commonly With Gastroesophageal Reflux, Compared With Nocturnal Sleep. Clinical Gastroenterology and Hepatology, 2015, 13, 94-99.	4.4	17
14	The effect of antireflux treatment on the frequency of awakenings from sleep in patients with Gastroesophageal reflux disease. Neurogastroenterology and Motility, 2015, 27, 237-245.	3.0	15
15	Sorting out the Relationship between Gastroesophageal Reflux Disease and Sleep. Current Gastroenterology Reports, 2021, 23, 15.	2.5	11
16	The Risk of Acute Myocardial Infarction in Patients With Gastroesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 2020, 26, 471-476.	2.4	11
17	Overlap Between GERD and Functional Esophageal Disorders - a Pivotal Mechanism for Treatment Failure. Current Treatment Options in Gastroenterology, 2019, 17, 161-164.	0.8	10
18	Management of Gastroesophageal Reflux Disease in the Elderly Patient. Drugs and Aging, 2019, 36, 1073-1081.	2.7	9

#	ARTICLE	IF	CITATIONS
19	Development of quality indicators for the diagnosis and management of achalasia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14118.	3.0	9
20	Severity of ineffective esophageal motility is associated with utilization of skeletal muscle relaxant medications. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13235.	3.0	8
21	High resolution vs conventional esophageal manometry in the assessment of esophageal motor disorders in patients with nonâ€cardiac chest pain. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13282.	3.0	7
22	Barrettâ€™s esophagus patients are becoming younger: analysis of a large United States dataset. <i>Esophagus</i> , 2020, 17, 190-196.	1.9	5
23	No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 606-615.	3.7	5
24	The relationship between gastroesophageal reflux disease and autism spectrum disorder in adult patients in the United States. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14295.	3.0	4
25	Durability of Esophageal Motor Disorders Identified on High-Resolution Esophageal Manometry: A Case Series. <i>Advances in Therapy</i> , 2020, 37, 2560-2571.	2.9	3
26	Protonâ€pump inhibitor use and the development of new ischemic heart disease in nonâ€cardiac chest pain patients. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13844.	3.0	3
27	Endoscopic Anti-Reflux Procedures: Ready for Clinical Use?. <i>Current Treatment Options in Gastroenterology</i> , 2021, 19, 399-420.	0.8	3
28	Commentary: the proton pump inhibitor test â€ does it have a role in eosinophilic oesophagitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 896-897.	3.7	1
29	Editorial: management of eosinophilic oesophagitis â€ efficacy vs. effectiveness. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 198-199.	3.7	1
30	Alteration in Integrated Relaxation Pressure During Successive Swallows in Subjects With Normal Manometry Versus Those With Esophagogastric Junction Outflow Obstruction. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 185-190.	2.4	1
31	Letter: oesophageal eosinophilia must be excluded before determining prevalence of eosinophilic oesophagitis - authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 629-629.	3.7	0
32	Letter: is there a relationship between Barrett's oesophagus length and body mass index? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 702-703.	3.7	0